Study of the behavior of hepatic function and blood coagulation in the course of oral administration of an estroprogestogen in low dosage
Pastore, A.R.; Gaeta, A.; Police, M.A.
Rivista Italiana di Ginecologia 57(3): 171-185
1976
ISSN/ISBN: 0035-6840 PMID: 1032427 Document Number: 432509
To study its effects on liver functions and on blood clotting, a new oral contraceptive (OC) containing 0.5 mg of quingestanol acetate, and 0.05 mg. of ethinyl estradiol was administered to 12 patients, aged 21-40, for 3 consecutive cycles. The patients were accurately examined before treatment, at the 2nd and 3rd month, and again 1 month after suspension of treatment. There were no significant modifications of clinical symptoms, or modifications of laboratory tests. In 5 cases only there was an increase in bilirubinemia; in a few other patients there were thromboelastogram variations. Both changes were not serious enough to cause either liver dysfunction or thromboembolism. It is, however, extremely important to examine regularly any patient on OC.